Pharmacokinetics of Oxaliplatin During Open Versus Laparoscopically Assisted Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC): An Experimental Study

Gesson-Paute, Amélie; Ferron, Gwénaël; Thomas, Fabienne; Lara, Emanuelle Cohen de; Chatelut, Étienne; Querleu, Denis

doi:10.1245/s10434-007-9571-9

Cited by 75 publications

(48 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a pig model, laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC), associated with an increased intra-abdominal pressure, resulted in higher drug absorption from the abdominal cavity to the systemic compartment when compared with the open abdomen, coliseum technique [55]. The practical use of highly increased intra-abdominal pressure is restricted by its adverse effect on the respiratory and hemodynamic systems.…”

Section: Intra-abdominal Pressurementioning

confidence: 99%

Pharmacological principles of intraperitoneal and bidirectional chemotherapy

Bree

Michelakis

Stamatiou

et al. 2017

Pleura and Peritoneum

View full text Add to dashboard Cite

Intraperitoneal chemotherapy is associated with a significant pharmacokinetic and pharmacodynamic benefit and can, alone or in combination with systemic chemotherapy (bidirectional chemotherapy), be used for treating primary and secondary peritoneal surface malignancies. Due to the peritoneal-plasma barrier, high intraperitoneal drug concentration can be achieved by intraperitoneal chemotherapy, whereas systemic concentration remains low. Bidirectional chemotherapy may provide in addition adequate drug concentrations from the side of the subperitoneal space to the peritoneal tumour nodules. Major pharmacological problems of intraperitoneal chemotherapy are limited tissue penetration and poor homogeneity of drug distribution to the entire seroperitoneal surface. Significant pharmacological determinants of intraperitoneal chemotherapy are choice of drug, drug dosage, solution volume, carrier solution, intra-abdominal pressure, temperature, duration, mode of administration, extent of peritonectomy and interindividual variability. Drugs most commonly applied for intraperitoneal chemotherapy include mitomycin C, cisplatin, carboplatin, oxaliplatin, irinotecan, 5-fluoruracil, gemcitabine, paclitaxel, docetaxel, doxorubicin, premetrexed and melphalan. The drugs and their doses that are used vary widely among centres. While the adequate drug choice for intraperitoneal and bidirectional chemotherapy is essential, randomized clinical trials to determine the most optimal drug or drug combination are lacking, and only eight retrospective comparative clinical studies are available. Further clinical pharmacological studies are required to determine the most effective drug regimen for intraperitoneal and bidirectional chemotherapy in various indications. In the future, reliable drug sensitivity testing and genetic profiling of peritoneal metastases will be needed for enabling patient-specific therapy.

show abstract

Section: Intra-abdominal Pressurementioning

confidence: 99%

Pharmacological principles of intraperitoneal and bidirectional chemotherapy

Bree

Michelakis

Stamatiou

et al. 2017

Pleura and Peritoneum

View full text Add to dashboard Cite

show abstract

“…In the present medical environment where there is a constant quest for minimally invasive procedures, two recent cohorts of patients treated with laparoscopic CRS and HIPEC versus laparotomy presented no significant differences in postoperative morbidity and mortality between the two approaches, identifying laparoscopic HIPEC as a safe and efficient alternative (67,75,76).…”

Section: Laparoscopic Hipecmentioning

confidence: 93%

“…However, in addition to the direct drug delivery system in open laparotomy, there have been advances in the minimally invasive surgical techniques, allowing for the introduction of the laparoscopic HIPEC therapy. In terms of efficacy, an animal study demonstrated increased drug perfusion with the laparoscopic technique (66,67).…”

Section: Direct Peritoneal Chemotherapymentioning

confidence: 99%

A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement

Beeharry

Yao

et al. 2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Peritoneal carcinomatosis (PC) is manifested in up to 40% of gastric cancer (GC) patients, after which their 5-year survival drops to less than 5%. The currently most acceptable treatment option for advanced GC (AGC) is systemic chemo and radio therapies with however generally very unsatisfying results and this led to a resurgence of interest in regional therapies like cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Small trials have indicated an association with prolonged survival when applying this technique to AGC manifesting with PC. High procedure-related morbidity and mortality associated with the CRS-HIPEC approach have however brought by a polemic on the merits of the latter: with the advent of regulatory approval of more effective as well as novel, more personalized treatment options in AGC, along with advances in tailoring investigational agents specifically for peritoneal delivery, there clearly is a need to outline the appropriate role of CRS-HIPEC in this disease.In a clear objective to improve the therapeutic efficiency of HIPEC, there have been immense developments in the technical aspects of this technology including the use of nanotechnology in more precise drug delivery systems (DDS) or choice of more efficient drugs such as gene-target technology, laparoscopy and so on. Henceforth, in this review, we will be highlighting the past and current status of the CRS + HIPEC procedure, shedding light on the pros and cons in order to boost up the efficiency of this multimodality approach.

show abstract

“…Recently, intraperitoneal chemohyperthermia has attracted further attention and been widely used throughout the world, achieving satisfactory therapeutic outcomes. [4][5][6] The National Cancer Research Institute in Italy has carried out stage II testing of intraperitoneal chemohyperthermia (cisplatin + mitomycin C) in 27 cases of recurrent ovarian cancer, and the two-year survival rate was 55%, with a median time to local tumor progression of 21.8 months. Of note, a stage III study of 415 patients with end-stage ovarian cancer showed that the median survival time in patients treated with combined chemotherapy via the venous and abdominal cavity routes was 65.6 months, while that of patients who received only intravenous chemotherapy was 49.7 months.…”

Section: Introductionmentioning

confidence: 99%

Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs) in vivo

Tang

Chen²,

Xue³

et al. 2011

IJN

View full text Add to dashboard Cite

Background:The purpose of this study was to develop intraperitoneal hyperthermic therapy based on magnetic fluid hyperthermia, nanoparticle-wrapped cisplatin chemotherapy, and magnetic particles of albumin. In addition, to combine the multiple-killing effects of hyperthermal targeting therapy, chemotherapy, and radiotherapy, the albumin-nanoparticle surfaces were linked with radionuclide 188 Re-labeled folic acid ligand ( 188 Re-folate-CDDP/HSA). Methods: Human serum albumin was labeled with 188 Re using the pre-tin method. Reaction time and optimal conditions of labeling were investigated. The particles were intravenously injected into mice, which were sacrificed at different time points. Radioactivity per gram of tissue of percent injected dose (% ID/g) was measured in vital organs. Re-folate-CDDP/HSA magnetic nanoparticles can be used in radionuclide-targeted cancer therapy. Surface-modified albumin nanoparticles with folic acid ligand-labeled radionuclide ( 188 Re) were successfully prepared, laying the foundation for a triple-killing effect of thermotherapy, chemotherapy, and radiation therapy.

show abstract

Pharmacokinetics of Oxaliplatin During Open Versus Laparoscopically Assisted Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC): An Experimental Study

Cited by 75 publications

References 16 publications

Pharmacological principles of intraperitoneal and bidirectional chemotherapy

Pharmacological principles of intraperitoneal and bidirectional chemotherapy

A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement

Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs) in vivo

Contact Info

Product

Resources

About